Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biofrontera ( (BFRI) ) has shared an update.
On October 20, 2025, Biofrontera Inc. finalized agreements with its former parent company, Biofrontera AG, to acquire all U.S. rights to Ameluz® and RhodoLED®. This strategic transaction involves a new earnout model replacing the previous transfer pricing model, which could impact the company’s revenue structure and market positioning in the U.S.
The most recent analyst rating on (BFRI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s overall score is driven by strong technical momentum and positive earnings call sentiment, offset by weak financial performance and valuation concerns. The company’s strategic shifts and growth prospects are promising, but profitability and cash flow challenges remain significant risks.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. operates in the pharmaceutical industry, focusing on dermatology products. Its primary products include Ameluz®, a prescription drug for skin cancer treatment, and RhodoLED®, a lamp used in photodynamic therapy. The company is focused on expanding its market presence in the United States.
Average Trading Volume: 174,555
Technical Sentiment Signal: Buy
Current Market Cap: $10.78M
For an in-depth examination of BFRI stock, go to TipRanks’ Overview page.